Organization, Agent, Virus/Disease and Keyword Indexes to news articles from 1994 issues of the Antiviral Agents Bulletin are presented below.
Index entries refer to the issue month and page numbers on which articles begin. Page numbers are listed only once. Thus, more than one article concerning the same topic may appear on the same page. The Keyword Index includes some subjects not covered by the Organization, Agent or Virus/Disease Indexes.
The full text of Bulletin news articles may be searched using the PTS Newsletter Database on the DIALOG (file 636) and DATA-STAR systems of online databases. Bulletin articles are also selectively indexed in the BioCommerce Abstracts and Directory and the PTS PROMT databases on several online systems.
New and recent subscribers desiring full sets of 1994 and earlier issues may contact the publisher to request information about rates and availability.
Organization Index
Abbott Labs. - Apr., p. 102; Oct., p. 291
Abt Associates, Inc. - Feb., p. 43
Academic Press - Oct., p. 299
Activated Cell Therapy - Sep., p. 268
Adatomed GmbH - Dec., p. 363
Advanced Technology Program - Nov., p. 332
Agouron Pharmaceuticals, Inc. - Feb., p. 36; Mar., p. 70; Oct., p. 291
Agracetus, Inc. - Nov., p. 332; Dec., p. 362
AIDS Action Baltimore, Inc. - Sep., p. 262
AIDS Clinical Trials Groups - May, p. 135
AIDS Project Los Angeles - Feb., p. 44
AIDS Vaccine Evaluation Units (AVEUs) - July, p. 204
Ajinomoto Co., Inc. - Feb., p. 41; Apr., p. 97
Allelix Biopharmaceuticals Inc. - May, p. 138
Alpha 1 Biomedicals, Inc. - Mar., p. 73; May, p. 131; Sep., p. 264; Dec., p. 357
Amarillo Cell Culture Co. - June, p. 169
American Biogenetic Sciences, Inc. - Oct., p. 296
American Cyanamid Co. (portions acquired in late 1994 by Amer. Home Prod.) - Aug., p. 230; Sep., p. 264
American Home Products Corp. - Feb., p. 33; June, p. 170; Sep., p. 264; Nov., p. 331
American Vaccine Corp. - Feb., p. 39
Amira Inc. - Aug., p. 230
AMRAD Corp. - June, p. 170
Antiretroviral Pregnancy Registry - Aug., p. 227
Anver Bioscience Design, Inc. - Feb., p. 44
Apollon Inc. - Sep., p. 268
Apotex Pharmaceuticals - Feb., p. 41
ARCH Development Corp. - July, p. 206
Army Medical Research and Development Command - Feb., p. 42
Astra AB - Apr., p. 97
ATIS (use HIV/AIDS Treatment Information Service)
Avid Therapeutics Inc. - Mar., p. 74; Apr., p. 103; July, p. 206
Baker Norton Pharmaceuticals, Inc. - Aug., p. 235
Barr Labs. - Oct., p. 300; Dec., p. 364
Baxter International - Sep., p. 268
Bayer AG - Apr., p. 97
Baylor College of Medicine - Apr., p. 103
Beavermade Ltd. - Feb., p. 41
Behring AG - June, p. 172
Behringwerke AG - Feb., p. 39
BIKEN Institute - Feb., p. 35
Bio-Rad Labs. - Dec., p. 362
BioChem Pharma Inc. - Apr., p. 98; June, p. 170; Nov., p. 321, 322, 324; Dec., p. 362
Biocine Corp. (acquired by Chiron in late 1994) - Feb., p. 42; June, p. 168; Aug., p. 233; Oct., p. 300; Nov., p. 324, 326, 328
Bioclones (Pty) Ltd. - Dec., p. 363
Biocontrol Technology, Inc. - Oct., p. 293
Biogen Corp. - Aug., p. 236; Nov., p. 333
Biomedical Research, Inc. - Feb., p. 43
Bioqual, Inc. - Aug., p. 232
BioServe Biotechnologies Ltd. - Sep., p. 267
Biotechnology Information Institute - Mar., p. 75
BioVac (subsidiary of BioChem Pharma Inc.) - June, p. 170
Boehringer Ingelheim Pharmaceuticals, Inc. - Apr., p. 97; Dec., p. 356
Boryung Pharmaceuticals Co. Ltd. - Nov., p. 328
Bristol-Myers Squibb Co. - Feb., p. 34; May, p. 137; June, p. 161, 164, 200, 202; Aug., p. 225; Oct., p. 295; Dec., p. 356
Burroughs Wellcome Co. (see also Wellcome) - Feb., p. 41; Mar., 65; Apr., p. 97, 103; May, p. 135; June, p. 171; July, p. 197; 199; Aug., p. 227; Sep., p. 257; 270; Oct., p. 290; 300; Nov., p. 321; Dec., p. 356; 358; 364
Cambridge Biotech Corp. - May, p. 138; July, p. 202; Dec., p. 359
Cambridge Research Biochemicals - Nov., p. 325
Cantab Pharmaceuticals PLC - Sep., p. 268
Castle Group - July, p. 201
CBR Labs. - Oct., p. 293
CDC National AIDS Treatment Clearinghouse - Nov., p. 332
CEL-SCI Corp. - Nov., p. 331
Celgene Corp. - Apr., p. 102; Oct., p. 297
Cell Genesys, Inc. - July, p. 200, 204
Cellcor, Inc. - Aug., p. 230
Center for Blood Research, Inc. - Oct., p. 293
Center for Special Immunology - Feb., p. 38
Centers for AIDS Research (CFARs) - Apr., p. 104
Centers for Disease Control and Prevention (CDC) - June, p. 170; Aug., p. 227, 233
Centre Nationale de Transfusion Sanguine - Oct., p. 291; Nov., p. 331
China National Biological Products Corp. - Dec., p. 362
Chiron Corp. - Feb., p. 42; June, p. 164, 168; July, p. 194; Aug., p. 233; Sep., p. 267; Oct., p. 300; Nov., p. 324, 326, 328, 330; Dec., p. 366
Chiron Vision Corp. - Dec., p. 353, 363
Chugai Pharmaceutical Co., Ltd. - Aug., p. 232; Sep., p. 267
Chulalongkorn Univ. - June, p. 171
Ciba-Geigy Ltd. - June, p. 168; July, p. 194; Aug., p. 233; Oct., p. 300; Nov., p. 324, 326; Dec., p. 357
Clearinghouse for Networked Information Discovery and Retrieval (CNIDR) - Dec., p. 363
Cleveland Clinic - July, p. 201
Clinical Chemistry Consultants, Inc. - Sep., p. 266
Columbia Univ. - Dec., p. 355
Community Research Initiative on AIDS - Aug., p. 231
Community Research Institute New England - Aug., p. 229
Connaught Labs. (subsidiary of Rhone-Poulenc Rorer) - Mar., p. 73; June, p. 170, 172
CPCRA (use Terry Beirn Community Programs for Clinical Research on AIDS)
Cryopharm Corp. - Sep., p. 265
CTS Chemical Industries - Nov., p. 328
Daiichi Pure Chemicals Co. - Oct., p. 300
Dainabbott Ltd. - Oct., p. 300
Dana-Farber Cancer Inst. - Apr., p. 104
Dartmouth College - Oct., p. 291
Davol Div., C.R. Bard Inc. - Apr., p. 103
Department of Defense - Feb., p. 33
Division of AIDS, NIAID - June, p. 172
DuPont Corp. - Dec., p. 362
DuPont Merck Pharmaceuticals - Feb., p. 40; Apr., p. 97
E. Merck AG - Nov., p. 331
Eisai Co., Ltd. - May, p. 130
Eli Lilly & Co. (use Lilly, Eli & Co.)
Emory Univ. - Mar., p. 74; Apr., p. 103
Epitec Ltd. - June, p. 171
Epitope Corp. - Dec., p. 363
Essex Chemical - Oct., p. 291
European Patent Office - Aug., p. 236
FDA Antiviral Drugs Advisory Committee - June, p. 161; Nov., p. 323
FDA Vaccines and Related Biological Products Advisory Commitee - Feb., p. 35
FDA - Feb., p. 42; Apr., p. 102; June, p. 165; July, p. 197; Sep., p. 259, 261; Nov., p. 331
Federal Trade Commission - Feb., p. 39; Nov., p. 331
Fitzsimmons Army Medical Center - Dec., p. 357
Forest Labs. - Dec., p. 360
Food and Drug Administration (use FDA)
Fox Chase Cancer Center - Mar., p. 74
Fred Hutchinson Cancer Research Center - Mar., p. 75; Sep., p. 268
FujiRebio Pharmaceuticals - Oct., p. 300
GA Investments SA - June, p. 171
Gallo, R.C. - Feb., p. 42
GelTex Pharmaceuticals, Inc. - Nov., p. 332
Gen-Probe Inc. - Sep., p. 267
Genelabs Technologies, Inc. - May, p. 137
Genentech Inc. - June, p. 164; July, p. 194; Dec., p. 359
Genesis Bio Pharmaceuticals - Feb., p. 39
Genetic Therapy, Inc. - May, p. 139
Genetics Institute (majority owned by Amer. Home Prod.) - Feb., p. 36
GenPharm International - July, p. 204
Genta Inc. - Aug., p. 231
Genta Jago Technologies B.V. - Aug., p. 231
Georgetown Univ. - Aug., p. 232
German Red Cross Blood Transfusion Service - Sep., p. 266
Gilead Sciences, Inc. - Feb., p. 40; Mar., p. 71; May, p. 138; Aug., p. 230, 232
Glaxo Holdings PLC - Apr., p. 97, 98; Nov., p. 321, 322
Green Cross Corp. - Apr., p. 102
Grelan Pharmaceutical - Nov., p. 328
Harvard Medical School - Apr., p. 104
Harvard School of Public Health - Mar., p. 67
Haworth Press - May, p. 139
Hayashibara Biochemical Labs. - June, p. 169
Health Professionals, Inc. - Feb., p. 38
Hedral Therapeutics, Inc. - Oct., p. 297
HEM Pharmaceuticals - Dec., p. 363
HemaCare Corp. - Feb., p. 37
HemaSure Inc. - Sep., p. 266
HemoCleanse, Inc. - Oct., p. 293; Dec., p. 362
HIV Vaccine Efficacy Trials Network (HIVNET) - Mar., p. 75
HIV/AIDS Treatment Information Service (ATIS) - Nov., p. 332
Hoechst AG - Apr., p. 97
Hoechst-Roussel - Oct., p. 297
Hoffmann-La Roche Inc. - Feb., p. 34; Mar., p. 73; Apr., p. 97, 102; May, p. 137, 138, 140; Aug., p. 226, 227; Sep., p. 264, 270; Nov., p. 326
Hoffmann-La Roche Ltd. - June, p. 169; Dec., p. 359
Howard Hughes Medical Institute - June, p. 173
Hybridon, Inc. - May, p. 133; July, p. 201; Aug., p. 233; Oct., p. 295
ICN Pharmaceuticals Inc. - June, p. 171; Aug., p. 233
ICOS Corp. - Oct., p. 297
IDC Holdings, Ltd. - Oct., p. 293
IDEXX Corp. - Dec., p. 366
IDT, Inc. - Oct., p. 293
Immune Response Corp. - Mar., p. 72; May, p. 138; June, p. 172; Aug., p. 232
Immunex Corp. - Sep., p. 264
Immunization Products Ltd. - Mar., p. 72; May, p. 138; Aug., p. 232
Immuno AG - Aug., p. 231
Immusol Inc. - Sep., p. 268
INCSTAR Corp. - Mar., p. 74
Institut National de la Sante et de la Recherche Medicale (INSERM) - Oct., p. 293
Institut Pasteur - Apr., p. 102; July, p. 202
Institute for Health Care Business Development - Mar., p. 76
Inter-Company Collaboration for AIDS Drug Development - Apr., p. 97; Sep., p. 261
Interferon Sciences, Inc. - Feb., p. 39; May, p. 140
International Conference on AIDS - Aug., p. 228
Internet - Dec., p. 363
Isis Pharmaceuticals, Inc. - Feb., p. 43; May, p. 130; Aug., p. 233; Nov., p. 325
Istituto Superiore di Santa - Mar., p. 74
Ivax Corp. - Aug., p. 235
Jagotec AG - Aug., p. 231
Japan Tobacco Co., Ltd. - Mar., p. 70; Dec., p. 360
Japanese Foundation for Cancer Research - Feb., p. 41
Japanese Ministry of Health and Welfare - Mar., p. 73; June, p. 169; July, p. 200
John Greenberg Library of Alternative Treatments - Feb., p. 44
Johns Hopkins Univ. School of Medicine - Feb., p. 40; July, p. 202
Johnson & Johnson Co. - Oct., p. 300
Johnson Matthey PLC - Oct., p. 296
JT Immunotech USA - July, p. 204
Kaketsuken - Oct., p. 300
Kyokuto Seiyaku Kogyo Inc. - Oct., p. 300
Lederle Praxis Biologicals - Sep., p. 264
LIDAK Pharmaceuticals - Nov., p. 328
Lilly, Eli & Co. - Feb., p. 36; Apr., p. 97, 102; June, p. 165
Marion Merrell Dow Inc. - Mar., p. 68
Matrix Pharmaceutical, Inc. - Oct., p. 289
Medarex, Inc. - Oct., p. 291; Nov., p. 331
Medeva PLC - Feb., p. 41; Mar., p. 73; June, p. 170, 171; Oct., p. 296; Nov., p. 333
Medical Biology Institute - Nov., p. 328
Medical College of Wisconsin - Apr., p. 100
MediChem Research, Inc. - Apr., p. 106; Sep., p. 270
MedImmune Inc. - July, p. 200; Sep., p. 264; Oct., p. 296
Merck & Co. - Feb., p. 35; Mar., p. 69; Apr., p. 97, 101; May, p. 141; June, p. 172; Dec., p. 362
Merck AG, E. (use E. Merck AG)
Merck Frosst Canada Inc. - Mar., p. 73
Microbiological Associates - Mar., p. 75
MicroGeneSys, Inc. - Feb., p. 33
Miles Inc. - Apr., p. 97
Miles Pharmaceutical - Mar., p. 74
Mochida Pharmaceutical Co., Ltd. - June, p. 169
Monsanto Corp. - Nov., p. 326
Multicenter AIDS Cohort Study - Sep., p. 257
Mundipharma Pharmaceutical Co. - Feb., p. 39
Murex Diagnostics Ltd. - Dec., p. 366
National Cancer Inst. (NCI) - Feb., p. 36; Mar., p. 74; Apr., p. 106; May, p. 129; Aug., p. 235; Dec., p. 364
National Cooperative Drug Discovery Groups - Apr., p. 104; May, p. 139
National Eye Institute (NEI) - Dec., p. 353
National Institute of Allergy and Infectious Diseases (NIAID) - June, p. 164, 172; July, p. 194; Aug., p. 232; Oct., p. 292
National Institute of Mental Health (NIMH) - Oct., p. 301
National Institutes of Health (use NIH)
National Library of Medicine (NLM) - Apr., p. 105
National Organization for Rare Diseases (NORD) - Apr., p. 103
National Task Force on AIDS Drug Development - Feb., p. 42
New England Medical Center - Sep., p. 268
New York Blood Center - Apr., p. 103
New York State Dept. of Health - Oct., p. 297
NIH - June, p. 164; July, p. 202, 205; Aug., p. 235; Sep., p. 267, 270
NIH Office of AIDS Research - Mar., p. 75
NIH Office of Research Integrity - Feb., p. 42
NIH Subcommittee to Review FIAU Studies - June, p. 166
Nippon Shoji Kaisha - July, p. 200
Nippon Zeon Co., Ltd. - Oct., p. 297
North American Biologicals, Inc. - Dec., p. 359
Northfield Labs. - Apr., p. 101
NovaGene Inc. - Apr., p. 103
Novopharm, Inc. - Oct., p. 300; Dec., p. 364
Oclassen Pharmaceuticals, Inc. - June, p. 165
Oregon Health Sciences Univ. - Oct., p. 297
Organetics Ltd. - Oct., p. 293
Organon Teknika Corp. - Dec., p. 363, 366
Ortho Diagnostic Systems Inc. - Oct., p. 300; Dec., p. 366
Otsuka Pharmaceutical Co., Ltd. - May, p. 134; June, p. 169; Oct., p. 300
Oxigene, Inc. - Dec., p. 363
Oxo Chemie GmbH - Dec., p. 359
Parke-Davis (use Warner-Lambert Co.)
Pasteur Merieux Serums et Vaccins (sub. of Rhone-Poulenc Rorer) - Feb., p. 39; Mar., p. 73; June, p. 172; Oct., p. 296
Paul, W.E. - Mar., p. 75
Perkin-Elmer Corp. - Apr., p. 102
Pfizer & Co. - Apr., p. 97
Pierre Fabre Medicaments - June, p. 172
Popovic, M. - Feb., p. 42
Population Council - June, p. 169
PRA Labs - Nov., p. 331
Procept Inc. - Apr., p. 104; Nov., p. 330
Progenics Pharmaceuticals, Inc. - Feb., p. 43; Apr., p. 104; Nov., p. 332
Proteus International PLC - Feb., p. 41; Mar., p. 73
Purdue Frederick Co. - Feb., p. 39
Repligen Corp. - Aug., p. 230
Rhone-Poulenc Rorer - Feb., p. 39; Mar., p. 72; May, p. 138; June, p. 172; Aug., p. 232; Oct., p. 296
Ribi ImmunoChem Research, Inc. - Nov., p. 327, 328
RiboGene, Inc. - Sep., p. 269
Ribozyme Pharmaceuticals, Inc. - Sep., p. 267
Roche Holding Ltd. - May, p. 138
Rockefeller Univ. - Oct., p. 297
San Francisco General Hospital - Nov., p. 330
Sandoz AG - Oct., p. 296
Schering-Plough K.K. - Mar., p. 73; June, p. 169
SciClone Pharmaceuticals, Inc. - May, p. 131; Sep., p. 264; Dec., p. 357
Sclavo SpA (acquired by Ciba-Geigy Ltd.) - Feb., p. 42; Dec., p. 357
Scripps Research Inst. - Mar., p. 72
SEARCH Alliance - Aug., p. 229
Searle, G.D. & Co. - Nov., p. 326
Seragen, Inc. - Feb., p. 41
Shaman Pharmaceuticals, Inc. - Dec., p. 360
Shanghai Institute of Biological Products - Dec., p. 362
Sheffield Medical Technologies Inc. - Oct., p. 293
Sigma-Tau S.p.A. - Apr., p. 97
Sloan-Kettering Memorial Cancer Inst. - May, p. 140
SmithKline Beecham Biologicals - Nov., p. 327; Dec., p. 362
SmithKline Beecham Corp. - Feb., p. 35, 39, 40; Apr., p. 97, 106; July, p. 193; Sep., p. 270; Nov., p. 325
South Australia government - Apr., p. 101
SPI Pharmaceuticals - Aug., p. 233
SRL, Inc. - Aug., p. 230
St. Vincent's Hospital (Sidney, Australia) - Oct., p. 295
Stanford Univ. - Sep., p. 268
Storz Instrument Co. - Aug., p. 230
Strategic Program for Innovative Research on AIDS Treatment (SPIRAT) - Sep., p. 268
Swiss Serum and Vaccine Institute - Feb., p. 39
Sylka Managing Co. Inc. - Nov., p. 329
Synbiotics Corp. - Dec., p. 366
Syntello Vaccine Development - Mar., p. 77
Syntex Corp. (acquired in late 1994 by Hoffmann-La Roche) - Apr., p. 97, 103; May, p. 138; Aug., p. 227; Sep., p. 264; Oct., p. 297; Nov., p. 328
SyStemix, Inc. - Nov., p. 325
T Cell Diagnostics, Inc. - Mar., p. 74
TargeTech, Inc. - Aug., p. 232
Targeted Genetics Corp. - Sep., p. 268, 270
Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) - Sep., p. 269
Teva Pharmaceuticals - Feb., p. 41
Therion Biologics Corp. - Mar., p. 71; Apr., p. 104; Sep., p. 262; Nov., p. 326
Treatment Activist Group - Mar., p. 73; Sep., p. 259
Tularik, Inc. - Apr., p. 101
U.K. Herpes Association - June, p. 171
U.S. Army Medical Research and Development Command - Nov., p. 332
U.S. Bioscience, Inc. - June, p. 174
U.S. Congress - Apr., p. 103
U.S. Court of Appeals for the Federal Circuit - Dec., p. 364
U.S. Dept. of Agriculture (USDA) - Oct., p. 297
United Biomedical, Inc. - June, p. 171, 201; Sep., p. 268; Oct., p. 300
Univ. of Alabama - July, p. 201, 204
Univ. of California (San Diego, CA) - Sep., p. 268; Nov., p. 330
Univ. of California - Apr., p. 100; May, p. 132; Dec., p. 366
Univ. of Colorado Health Science Center - May, p. 139
Univ. of Georgia - Sep., p. 265
Univ. of Gothenburg - Mar., p. 77
Univ. of Illinois at Chicago - Apr., p. 106
Univ. of North Carolina - Sep., p. 267
Univ. of Pennsylvania - Sep., p. 268
Univ. of Southern California - Dec., p. 359
Univ. of Washington - Mar., p. 75
Upjohn Co. - May, p. 138; July, p. 199; Oct., p. 296
Varmus, H. - Feb., p. 40
Verex Laboratories Inc. - Dec., p. 358
Verigen Inc. - Feb., p. 38
Vestar Inc. - Nov., p. 330
Viagene, Inc. - Apr., p. 102; Sep., p. 267; Nov., p. 330; Dec., p. 361
Vical Inc. - May, p. 139, 141; Oct., p. 296; Nov., p. 330
VIMRx Pharmaceuticals Inc. - Apr., p. 103
Viratek Inc. - June, p. 171; Aug., p. 233
Virotech Inc. - Oct., p. 293
VZV Research Foundation - Nov., p. 332
W.R. Grace & Co. - Nov., p. 332
Walter Reed Army Inst. of Research (WRAIR) - Feb., p. 33; Nov., p. 324, 328; Dec., p. 357
Warner Wellcome Consumer Health - Feb., p. 41
Warner-Lambert Co. - Feb., p. 40, 41; June, p. 170; July, p. 206
Washington Adventist Hospital - Sep., p. 267
Washington Hospital Center - Sep., p. 267
Wellcome Foundation - Feb., p. 41
Wellcome PLC (see also Burroughs Wellcome Co.) - Apr., p. 98; July, p. 202
Western Australia - June, p. 170
WHO Global Programme on AIDS - Nov., p. 324
Wistar Institute - Feb., p. 36
Wyeth-Ayerst Pharmaceuticals - June, p. 170
Xenotech, L.P. - July, p. 204
Yamanouchi Europe - Nov., p. 328
Yamanouchi Pharmaceutical Co., Ltd. - June, p. 169
Yamasa Corp. - July, p. 200
Zeneca Ltd. - Nov., p. 325
Agent Index
(-)-3'-thiacytidine (use 3TC)
(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (use GS 504)
2-aminopurines - Sep., p. 270
2',3'-didehydro-2',3'-dideoxythymidine (use D4T)
2,5A-antisense oligonucleotide conjugates - July, p. 201
3'-thiacytidine (use 3TC for HIV; lamivudine for hepatitis treatment)
3TC - Apr., p. 97, 98; Nov., p. 321, 322; Dec., p. 362
5-fluorouracil - Oct., p. 289
9-(2-phosphonylmethoxyethyl)adenine (use PMEA)
70K protein, HIV antibodies - Dec., p. 359
256U87 (use valaciclovir)
348U87 - May, p. 135
882C87 - May, p. 135; June, p. 171
A-80987 - Oct., p. 291
ABT-538 - Oct., p. 291
Accell gene guns - Nov., p. 332; Dec., p. 362
AccuSite Injectable Gel - Oct., p. 289
acetylsalicylic acid (use aspirin)
acridine derivatives - Sep., p. 265
acyclovir - May, p. 135; June, p. 171; July, p. 199; Sep., p. 270; Oct., p. 290, 295
acyclovir, controlled release - Aug., p. 231
acyclovir, generic - Feb., p. 41
acyclovir, OTC - Feb., p. 41; July, p. 197
acyclovir, topical - Nov., p. 328
acyclovir/AZT combination - Sep., p. 257; Oct., p. 295
Adatomed Silicone Oil - Dec., p. 363
afovirsen (use ISIS 2105)
AG1343 - Oct., p. 291
AG1350 - Feb., p. 36
ALFERON N Injection - Feb., p. 39
alpha 1-antitrypsin - Oct., p. 297
alum adjuvant - Nov., p. 328
alvercept sudotox [use CD4(178)-PE40]
ALX40-4C - May, p. 138
AM285 - Aug., p. 230
amantadine - Dec., p. 360
Ampligen - Dec., p. 363
antigen-coated diamond particle vaccines - Apr., p. 100
antisense oligonucleotide-2,5A conjugates - July, p. 201
antisense oligonucleotide-asialoglycoprotein conjugates - Aug., p. 232
antisense oligonucleotides - Sep., p. 267
antisense oligonucleotides, CMV - May, p. 130
antisense oligonucleotides, HIV - May, p. 133; July, p. 201; Aug., p. 233; Oct., p. 295
antisense oligonucleotides, viral 5' cap mRNA - Feb., p. 43
aspirin - Aug., p. 231
Astragalus plants - Feb., p. 44
autoimmune immune globulins - Dec., p. 359
autolymphocyte therapy (ALT) - Aug., p. 230
AZT - Mar., p. 65, 67, 71, 73, 74; Apr., p. 97, 99, 103; May, p. 129, 135, 137, 138; July, p. 201, 202; Aug., p. 227; Oct., p. 297, 300; Dec., p. 356
AZT Efficiently Controlled (Aztec) - Dec., p. 358
AZT, generic - Feb., p. 41; Dec., p. 364
AZT-DDI conjugates - Aug., p. 235
AZT/3TC combination - Nov., p. 321
AZT/acyclovir combination - Sep., p. 257; Oct., p. 295
beta2-microglobulin HIV vaccines - Oct., p. 293
BHAP-E (use delaveridine mesylate)
BI-RG-587 (use nevirapine)
BioLogic-HT - Oct., p. 293; Dec., p. 362
bis(POM)PMEA (use GS 840)
bovine immunodeficiency virus vaccine (for HIV) - Nov., p. 329
brominated psoralens - Sep., p. 265
bucast - Mar., p. 68
BV-araU - July, p. 200; Oct., p. 295
calanolides - Apr., p. 106; Sep., p. 270
Calophyllum plants - Sep., p. 270; Dec., p. 360
carrageenan - June, p. 169
castanospermine, 6-O-butanoyl- (use bucast)
CD4 inserted into erythrocytes - Oct., p. 293
CD4 liposomes - Oct., p. 293
CD4(178)-PE40 - Oct., p. 296
CD4+ T-cells, ex vivo expansion - Sep., p. 268
CD4-based therapeutics - Apr., p. 104; Nov., p. 330
cell-transfer immune reconstitution - Feb., p. 38
cholera toxin B vaccine carriers/adjuvants - Mar., p. 77
CMV gB vaccines - Aug., p. 233
CMV IE84 - Sep., p. 267
CMV naked DNA vaccines - Oct., p. 296
CMV protein kinase - July, p. 206
conocurvone - June, p. 170
Conospermun (Smokebush) - June, p. 170
controlled release AZT - Dec., p. 358
costatolides - Apr., p. 106
Croton plants - Dec., p. 360
curcumin - Aug., p. 229
cyclocreatine - Aug., p. 230
cytokines - Aug., p. 228; Nov., p. 331
cytotoxic lymphocyte maturation factor - Feb., p. 36
D4T - Feb., p. 34; June, p. 161; Aug., p. 225
DAB389IL-2 (use IL-2 Fusion Toxin)
DDC - Mar., p. 73; May, p. 137; Aug., p. 226
DDI - Apr., p. 97; May, p. 129, 135, 137; July, p. 202; Dec., p. 356
decoy vaccines - Apr., p. 100
delaveridine mesylate - May, p. 138
deuterium oxide - Apr., p. 102
dideoxyadenosine, 2'-fluoro-2',3'- (use F-ddA)
dideoxyinosine, 2-fluoro-2,3- (use F-ddI)
dideoxynucleosides, dimeric - Aug., p. 235
diphtheria toxin, HIV activated gene - May, p. 139
Disabled Infectious Single Cycle (DISC) vaccines - Sep., p. 268
docosanol - Nov., p. 328
entomopoxvirus vaccine vectors - Mar., p. 71
F-ddA - June, p. 174
F-ddI - June, p. 174
famciclovir - Feb., p. 40; July, p. 193; Sep., p. 270; Nov., p. 325
Famvir (use famciclovir)
fialuridine (use FIAU)
FIAU - June, p. 165, 166
FIV immunodiagnostics - Dec., p. 366
Flumadine - Dec., p. 360
foscarnet, alkyl-glycerol analog - Nov., p. 330
fowlpox virus vaccine vectors - Oct., p. 297
Gamimune N IVIG - Mar., p. 74
ganciclovir - May, p. 138; Sep., p. 264
ganciclovir, implants - Dec., p. 353
ganciclovir, oral - Aug., p. 227; Nov., p. 323
Gastrogard R - Apr., p. 101
GEM 91 - May, p. 133; July, p. 201; Aug., p. 233; Oct., p. 295
gene therapy vectors - May, p. 132; July, p. 200; Oct., p. 301
gene therapy, HIV - Dec., p. 362
Geomatrix (controlled release) - Aug., p. 231
gibbon ape leukemia virus vectors - Oct., p. 301
GLQ223 - May, p. 137
GS 504 - Feb., p. 40; Mar., p. 71; May, p. 138
GS 504, eye drops - Aug., p. 230
GS 804 - Mar., p. 71; Aug., p. 232
guanine, 9-(4-hydroxy-3-hydroxymethylbut-1-yl) (use famciclovir)
Havrix - Feb., p. 35; Dec., p. 362
Hepa-Gen-3 - June, p. 171
hepatitis A vaccines - Feb., p. 35; Mar., p. 73; June, p. 172; Oct., p. 296; Dec., p. 362
hepatitis B reverse transcriptase inhibitors - Mar., p. 74
hepatitis B surface antigen vaccines - June, p. 171, 172; Aug., p. 236; Nov., p. 333
hepatitis B vaccines - Aug., p. 236
hepatitis B vaccines, oral - Feb., p. 41; Mar., p. 73
hepatitis C antibodies - Aug., p. 232
hepatitis C diagnostics - Oct., p. 300; Dec., p. 366
hepatitis C vaccines - Mar., p. 73; Oct., p. 300
hepatitis C vaccines, oral - Feb., p. 41
hepatitis E virus vaccines - Oct., p. 292
herpes simplex virus (use HSV)
HIV alpha-glucosidase I inhibitors - Mar., p. 68
HIV antibodies, 70K protein - Dec., p. 359
HIV bispecific antibodies - Oct., p. 291; Nov., p. 331
HIV furin inhibitors - Oct., p. 297
HIV gene therapy - July, p. 200
HIV gene therapy vaccines - Apr., p. 102; Nov., p. 332
HIV gene therapy, DNA vaccines - Sep., p. 268; Oct., p. 296
HIV gene therapy, retroviral vectors - May, p. 139; Nov., p. 330; Dec., p. 361
HIV gene therapy, T-cells - Sep., p. 268, 270
HIV gp120 radioisotope conjugates - Nov., p. 332
HIV gp120 vaccines - Feb., p. 43
HIV gp160 vaccines - Feb., p. 33; June, p. 164; Aug., p. 231
HIV immune globulins - Feb., p. 37
HIV ImmunoTherapeutic from Viagene [use HIV-IT (V)]
HIV integrase inhibitors - Feb., p. 40
HIV LTR inhibitors - Aug., p. 229
HIV peptomers - Aug., p. 235
HIV porcine immune globulins - Feb., p. 38
HIV protease inhibitors - Feb., p. 34, 36, 40; Mar., p. 69, 70; Apr., p. 97, 102; Aug., p. 235; Sep., p. 261, 262; Oct., p. 291; Nov., p. 326; Dec., p. 360
HIV ribozymes - Sep., p. 267, 268
HIV RNase H inhibitors - Apr., p. 102
HIV Tat inhibitors - May, p. 138
HIV transcription repressors - Sep., p. 265
HIV vaccines - Feb., p. 40; July, p. 204
HIV vaccines, controlled release - Dec., p. 359
HIV vaccines, inactivated - Mar., p. 72; May, p. 138; June, p. 172; Aug., p. 232
HIV vaccines, synthetic peptides - June, p. 171; July, p. 201; Aug., p. 230; Sep., p. 268
HIV vaccines, vaccinia virus vectors - Mar., p. 71; Apr., p. 104
HIV-activated CD8+ T-cells - July, p. 200
HIV-binding phosphorothioate oligonucleotides - Nov., p. 325
HIV-IT (V) - Apr., p. 102; Nov., p. 330; Dec., p. 361
HIVID (use DDC)
HIVMN gp120 vaccine - June, p. 164; July, p. 194; Nov., p. 324; Dec., p. 359
HIVSF gp120 vaccine - June, p. 164; July, p. 194; Nov., p. 324, 328
Homalnthus plants - Aug., p. 235
HPMPC (use GS 504)
HSV UL13 protein kinase - July, p. 206
HSV vaccines - Sep., p. 264
HSV VP16 transactivator protein - Apr., p. 101
HSV-2 DISC vaccine - Sep., p. 268
HSV-2 gD vaccine - June, p. 168; Nov., p. 327
hypericin, oral - Apr., p. 103
hyperthermia, whole-body extracorporeal - Oct., p. 293; Dec., p. 362
IL-2 Fusion Toxin - Feb., p. 41
IL-2 gene therapy - Sep., p. 270
IL-2, polyethylene glycol-modified - Mar., p. 73
immune globulin and peripheral blood lymphocytes - Feb., p. 38
immune globulins, autoimmune - Dec., p. 359
immune globulins, RSV - July, p. 200
immune modulators - Feb., p. 36; July, p. 201
immunomodulatory polysaccharides - Feb., p. 44
Immupath - Feb., p. 37
influenza vaccines - June, p. 170; Aug., p. 233; Sep., p. 264
interferon, alfa-n1 - June, p. 169
interferon, alfa-n3 - Feb., p. 39; May, p. 140
interferon, alpha - Mar., p. 73
interferon, alpha-2a - June, p. 169
interferon, alpha-2b - Mar., p. 73; May, p. 131; June, p. 169; Dec., p. 357
interferon, leukocyte-derived - May, p. 140
interferon, lymphoblastoid - June, p. 169; Dec., p. 357
interleukin-10 - Aug., p. 235
interleukin-12 - Feb., p. 36
interleukin-2 (use IL-2)
Intron A (use interferon, alpha-2b)
ISIS 2105 - Aug., p. 233
ISIS 2922 - May, p. 130
ISIS 5320 - Nov., p. 325
Kaposi's sarcoma-associated virus - Dec., p. 355
KNI-272 - Dec., p. 360
kynostatin - Dec., p. 360
L-735,524 - Feb., p. 40; Mar., p. 69; Apr., p. 97
lamivudine - Nov., p. 324
LeukoVir-MB Filter - Sep., p. 266
LIDAKOL - Nov., p. 328
Liposome-CD4 - Oct., p. 293
liposome-encapsulated MPL adjuvant - Nov., p. 328
MDX-240 - Oct., p. 291; Nov., p. 331
measles/mumps/rubella vaccines - June, p. 172; Dec., p. 362
metal poly-oxometallates - Oct., p. 296
methylene blue - Sep., p. 266
MF59 adjuvant - July, p. 194; Aug., p. 233; Nov., p. 328
monoclonal antibodies, human-like - July, p. 204
monophosphoryl lipid A - Nov., p. 327, 328
muramyl tripeptide phosphatidylethanolamine - Nov., p. 328
n-docosanol - Nov., p. 328
naked DNA vaccines - May, p. 141
natural killer-cell stimulatory factor - Feb., p. 36
nevirapine - Apr., p. 97; May, p. 135; Dec., p. 356
nojirimycin, N-butyldeoxy- - Mar., p. 68
OPC-8212 (use vesnarinone)
Oral Vironostika HIV-1 Microelisa System - Dec., p. 363
OraSure HIV Oral Specimen Collection Device - Dec., p. 363
oxoferin - Dec., p. 359
PASSHIV-1 - Feb., p. 38
penciclovir - July, p. 193
peptoid compounds - Nov., p. 330
phorbol-13-acetate, 12-deoxy- (use prostratin)
phosphorothioate oligonucleotides, HIV-binding - Nov., p. 325
photoinactivation, blood - Apr., p. 103; Sep., p. 265
PIC 024 - Apr., p. 104; Nov., p. 330
PKR, interferon-inducer - Sep., p. 269
platinum complexes - Oct., p. 296
PMEA - Mar., p. 71
PMEA, bis pivaloyoxylmethyl (use GS 804)
poliovirus vaccine, inactivated (IPV) - Apr., p. 102
poly ADP-ribosyl transferase - Dec., p. 363
poly I:poly (C12U) - Dec., p. 363
poly(lactic-coglycolic)acid microsphere vaccines - Dec., p. 359
polyethylene glycol-modified IL-2 - Mar., p. 73
polymer-based drug, oral - Nov., p. 332
proanthocyanidin polymers - Dec., p. 360
ProScan-A - Nov., p. 332
prostratin - Aug., p. 235
ProSys - Apr., p. 104
protein kinase, interferon-induced - Sep., p. 269
Provax HIV gp120 vaccine - Feb., p. 43
Provir - Dec., p. 360
PRV/Marker - Apr., p. 103
pseudorabies vaccines - Apr., p. 103
psoralens, protein activated - Sep., p. 266
pyridinone (use L-735,524)
pyrimidinedione, 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodo-2,4(1H,3H)- (use FIAU)
pyrimidones, dibenzyl-5-hydroxyl-2- - Aug., p. 235
QS-21 Stimulon adjuvant - July, p. 202; Dec., p. 359
Quantiplex HSV RNA - Oct., p. 300
quinolinone, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- (use vesnarinone)
rabies vaccines - Feb., p. 39; June, p. 172
Rabipur - Feb., p. 39
RBC-CD4 - Oct., p. 293
Recombivax-HB - June, p. 172
red algae (Rhodophyta) - June, p. 169
red blood cells-CD4 - Oct., p. 293
RespiGam - July, p. 200; Sep., p. 264; Oct., p. 296
reverse transcriptase inhibitors, non-nucleosides - Mar., p. 74; Apr., p. 103; May, p. 138
rhinovirus type 14 3C protease - Mar., p. 70
ribavirin, aerosol - Aug., p. 233
ribavirin, oral - June, p. 171
rimantadine HCl - Dec., p. 360
Ro 31-8959 (use saquinavir)
Roferon A (use interferon, alpha-2a)
rotavirus bovine colustrum - Apr., p. 101
rotavirus vaccines - Nov., p. 331
RP400c - Aug., p. 230
RSV Fab single-chain antibody fragments - Mar., p. 72
RSV immune globulins - July, p. 200; Sep., p. 264; Oct., p. 296
RSV single-chain antibody fragments - July, p. 205
SAF/2 adjuvant - Nov., p. 328
saquinavir - Apr., p. 97; Sep., p. 259, 261; Nov., p. 326; Dec., p. 356
SC-52151 - Nov., p. 326
Scriptene - Aug., p. 235
selenocysteine - Sep., p. 265
serum thiols assay - Dec., p. 363
SIV vaccines, vaccinia virus vectors - Mar., p. 71
sorivudine (use BV-araU)
SP-303 - Dec., p. 360
stavudine (use D4T)
Stimulon adjuvants - July, p. 202; Dec., p. 359
sulfated polysaccharides - June, p. 169
Sumiferon - June, p. 169
swinepox vaccine vectors - Mar., p. 71
Symmetrel - Dec., p. 360
synovir (use thalidomide)
TBC-3B - Mar., p. 71
tetrachlorodecaoxygen - Dec., p. 359
thalidomide - Apr., p. 102; Oct., p. 297
threonyl muramyl dipeptide adjuvant - Nov., p. 328
thymosin alpha 1 - Mar., p. 73; May, p. 131; Sep., p. 264; Dec., p. 357
tragacanth gums - Feb., p. 44
transcription inhibitors - Apr., p. 101
TRAx CD4 and CD8 diagnostics - Mar., p. 74
trichosanthin (use GLQ223)
tumor suppressor protein p53 - Sep., p. 267
U-90,152 (use delaveridine mesylate)
uracil, (E)-5-(2-bromovinyl)arabinofuranosyl (use BV-araU)
Usevir (use BV-araU) - July, p. 200
vaccines, retroviral vectors - May, p. 132
vaginal gels, antiviral - June, p. 169
valaciclovir - May, p. 135; July, p. 202
Valtrex (use valaciclovir)
Vaqta - Mar., p. 73
varicella-zoster virus (use VZV)
Varivax - Feb., p. 35
VaxSyn HIV-1 - Feb., p. 33; June, p. 164
VectorVax FP-N - Oct., p. 297
vesnarinone - May, p. 134
Videx (use DDI)
ViraCHEK/FIV immunodiagnostics - Dec., p. 366
viral inactivation, blood - Sep., p. 266
Virazole (use ribavirin)
Virend - Dec., p. 360
VZV protein kinase - July, p. 206
VZV vaccines - Feb., p. 35
Zerit (use D4T)
Zonavir (use 882C87)
Virus/Disease Index
bovine immunodeficiency virus - Nov. p. 329
bronchopulmonary dysplasia - Oct., p. 296
cachexia - Apr., p. 102
chickenpox - Nov., p. 332
chronic fatigue syndrome - Oct., p. 299
chronic obstructive pulmonary disease - Mar., p. 70
CMV (usually CMV retinitis) - Feb., p. 40, 44; Apr., p. 101; May, p. 130, 135, 138; July, p. 206; Aug., p. 227, 230, 233; Sep., p. 264, 266, 267; Nov., p. 323, 330; Dec., p. 353, 363
congenital heart disease - Oct., p. 296
cytomegalovirus (use CMV)
depression - June, p. 169
encephalomyocarditis virus - Feb., p. 44
Epstein-Barr virus - Apr., p. 100, 101; Sep., p. 266
f6 bacteriophage - Sep., p. 265
feline immunodeficiency virus (FIV) - Dec., p. 366
fowlpox - Oct., p. 297
genital herpes (use HSV-2)
genital warts (use HPV)
gibbon ape leukemia virus - Oct., p. 301
graft-versus-host disease - Mar., p. 74
hantaviruses - Aug., p. 233, 235
hepatitis A - Feb., p. 35; Mar., p. 73; June, p. 172; Oct., p. 296; Dec., p. 362
hepatitis B - Feb., p. 41; Mar., p. 73, 74; Apr., p. 103; May, p. 131, 141; June, p. 165, 166, 171, 172; Aug., p. 230, 232, 236; Sep., p. 264; Nov., p. 324, 333; Dec., p. 357, 363
hepatitis C - Feb., p. 39, 41; Mar., p. 73, 74; Apr., p. 103; May, p. 141; June, p. 169, 171; Aug., p. 232, 235; Sep., p. 264; Oct., p. 300; Dec., p. 357, 366
hepatitis E virus - Oct., p. 292
hepatitis viruses - Sep., p. 266
herpes labialis (use HSV-1)
herpes zoster (see also VZV) - Feb., p. 40; May, p. 135; June, p. 171; July, p. 199, 200, 202; Oct., p. 295; Nov., p. 332
herpes simplex virus (see HSV entries)
herpesviruses - Aug., p. 230; Sep., p. 257, 270
herpesviruses, Kaposi's sarcoma-associated - Dec., p. 355
HIV - Feb., p. 33, 34, 36, 37, 38, 39, 40, 41, 42, 43, 44; Mar., p. 67, 68, 69, 71, 72, 73, 74, 75; Apr., p. 97, 98, 99, 100, 101, 102, 103, 104, 105, 106; May, p. 132, 133, 134, 135, 137, 138, 139; June, p. 161, 164, 169, 170, 171, 172, 173, 174; July, p. 194, 200, 201, 202, 204; Aug., p. 225, 226, 228, 229, 230, 231, 232, 233, 235; Sep., p. 257, 259, 261, 262, 265, 266, 267, 268, 269, 270; Oct., p. 291, 293, 295, 296, 297, 300; Nov., p. 321, 322, 324, 325, 326, 328, 329, 330, 332; Dec., p. 355, 356, 358, 359, 360, 361, 362, 363, 364
HIV maternal transmission - Mar., p. 65; July, p. 201; Aug., p. 227; Oct., p. 297
HIV, nonsyncytia-inducing - Aug., p. 228
HIV, pediatric - May, p. 129
HIV progression - Dec., p. 363
HIV-2 - Apr., p. 102; Nov., p. 330
HPV - Feb., p. 39; Mar., p. 71; May, p. 138, 140, 141; Aug., p. 233; Oct., p. 289
HSV - Feb., p. 41; May, p. 141; June, p. 171; July, p. 206; Sep., p. 264
HSV-1 - May, p. 135; July, p. 199; Aug., p. 231; Nov., p. 328, 330
HSV-2 - Feb., p. 40, 41; May, p. 135, 140; June, p. 168; July, p. 197, 199; Aug., p. 231; Sep., p. 268; Oct., p. 290; Nov., p. 325, 327, 328; Dec., p. 360
human herpesvirus-6 (HHV-6) - Apr., p. 100
human papillomavirus (use HPV)
influenza A and B - Feb., p. 36; May, p. 141; June, p. 170; Aug., p. 233; Sep., p. 264; Dec., p. 360
interstitial pneumonia - June, p. 169
Kaposi's sarcoma - Dec., p. 355
lymphoma, non B-cell - May, p. 132
measles - June, p. 172; Dec., p. 362
mixed connective tissue disease - Dec., p. 359
mumps - June, p. 172; Dec., p. 362
murine leukemia virus - Feb., p. 44; Mar., p. 75
Newcastle disease - Oct., p. 297
oncogenic viruses - May, p. 132
oxidative stress - Dec., p. 363
poliovirus - Apr., p. 102; Aug., p. 235
pseudorabies - Apr., p. 103
Punta toro virus - Feb., p. 44
rabies virus - Feb., p. 39
respiratory syncytial virus (use RSV)
restenosis - Sep., p. 267
retina detachment - Dec., p. 363
rhinoviruses - Mar., p. 70
rotavirus - Apr., p. 101; Nov., p. 331, 332
RSV - Mar., p. 72; Apr., p. 101; July, p. 200, 205; Sep., p. 264; Oct., p. 296; Dec., p. 360
rubella - June, p. 172; Dec., p. 362
sexually transmitted diseases - June, p. 169
shingles (use herpes zoster; see also varicella-zoster virus)
Sin Hombre virus (see also hantaviruses) - Aug., p. 233
SIV - Mar., p. 71; Apr., p. 104
suicide - June, p. 169
systemic lupus erythematosus - Dec., p. 359
varicella-zoster virus (use VZV)
VZV (see also herpes zoster) - Feb., p. 35; May, p. 135; June, p. 171; July, p. 193, 199, 200, 202, 206; Oct., p. 295; Nov., p. 332
Keyword Index
adverse event reporting - July, p. 200; Nov., p. 331
AIDS activists - Nov., p. 326
AIDSDRUGS database - Apr., p. 105
AIDSLINE database - Apr., p. 105
AIDSPAT, Internet news group - Dec., p. 363
AIDSTRIALS database - Apr., p. 105
animal therapeutics approvals - Oct., p. 297
approval, U.K. - Feb., p. 40
approvals - Mar., p. 74
approvals, accelerated - June, p. 161; Aug., p. 225; Sep., p. 259, 261, 262
AZT sales - Apr., p. 103
baboons, HIV models - Nov., p. 330
bankruptcy - July, p. 202
Canada - June, p. 170
clinical trial regulations - Nov., p. 331
clinical trials halted - Feb., p. 33; Aug., p. 230; Nov., p. 326
clinical trials - Feb., p. 34, 37, 38, 40; Mar., p. 65, 67, 68, 69, 71, 72, 73, 74, 75; Apr., p. 97, 99, 101, 102, 103; May, p. 129, 130, 131, 133, 134, 135, 137, 138; June, p. 165, 166, 168, 171; July, p. 200, 201; Aug., p. 225, 226, 227, 229, 230, 231, 232, 233; Sep., p. 261, 262, 268; Oct., p. 289, 290, 291, 293, 295, 296, 297; Nov., p. 321, 323, 324, 325, 327, 328, 329, 330; Dec., p. 353, 356, 357, 358, 359, 360, 361, 362, 363
clinical trials, large-scale HIV - June, p. 164; July, p. 194; Nov., p. 324
co-promotion agreements - July, p. 199
Collaborative Research and Development Agreements (CRADAs) - Mar., p. 75; Oct., p. 301
community-based trials - Sep., p. 269
Concorde Study - April, p. 99
contract awards - Feb., p. 43; Mar., p. 75; June, p. 170
corporate disputes - Mar., p. 72; June, p. 171
corporate linkages - Feb., p. 33, 36, 41; Mar., p. 70, 73; Apr., p. 101, 102, 103; May, p. 131, 138, 139; June, p. 172; July, p. 199; Aug., p. 232; Sep., p. 267; Oct., p. 296; Nov., p. 325, 330; Dec., p. 359, 362, 363
corporate restructuring - May, p. 138; Aug., p. 230, 233; Sep., p. 267; Oct., p. 296; Nov., p. 326, 331; Dec., p. 360
criminal charges - Feb., p. 42
crystal structures - Mar., p. 70
cytokine validation - Nov., p. 331
cytotoxic T-cell immunity - Feb., p. 36
databases - Apr., p. 105; Nov., p. 332; Dec., p. 363
Directory of Biotechnology Information Resources - Apr., p. 105
drug approvals - July, p. 202
epidemiology - Apr., p. 102; July, p. 197; Aug., p. 227; Sep., p. 257; Dec., p. 355, 360
establishment license revoked - Feb., p. 42
ethnobotany - Dec., p. 360
European Community - June, p. 172
expanded access - Nov., p. 326
extortion - June, p. 171
FDA approvals - Feb., p. 35; July, p. 193; Aug., p. 225, 226, 227; Nov., p. 323; Dec., p. 363
Federal Bio-Technology Transfer Directory - Mar., p. 75
Finland - Dec., p. 362
food additives, antiviral - Feb., p. 44
France, approvals - Feb., p. 41
gene amplification - Apr., p. 102
grant awards - Apr., p. 104; May, p. 139; June, p. 170; July, p. 204; Sep., p. 268, 269; Nov., p. 332
heat sensitivity, HIV - Dec., p. 362
HIV radiodiagnostic imaging - Nov., p. 332
HIV research grants, minorities - June, p. 172
HIV reservoirs - Aug., p. 228
HIV viral burden - Aug., p. 228
HIV-infection co-factors - Apr., p. 100
HIV-infection from vaccines - June, p. 164
HuMab-Mouse system - July, p. 204
Human Immunodeficiency Virus (HIV) Research Program - Feb., p. 42
injunctions granted - Dec., p. 364, 366
insider trading - July, p. 200; Dec., p. 359, 362
Israeli markets - Feb., p. 41
Japan - Aug., p. 230
Journal of Chronic Fatigue Syndrome - Oct., p. 299
Journal of Pharmaceutical Care in HIV/AIDS Treatment - May, p. 139
lab safety, HIV - June, p. 173
licensing - Feb., p. 36, 39, 41, 44; Mar., p. 74, 76; Apr., p. 98, 102, 104, 106; May, p. 131, 171; June, p. 174; July, p. 205; Aug., p. 230, 232, 235; Sep., p. 264, 270; Oct., p. 293, 296, 297, 300, 301; Nov., p. 328, 330; Dec., p. 358, 359, 362, 363
licensing, federal government - Mar., p. 75
ligase chain reaction - Apr., p. 102
long-term survivors, HIV - Aug., p. 228
manufacturing facilities - Aug., p. 233
mice testing - Mar., p. 72
mucosal immunity - July, p. 204
mucosal vaccines - Mar., p. 77
NDA filings - Feb., p. 34; June, p. 171; Aug., p. 227
new companies - July, p. 201; Oct., p. 297
NIH budget - Mar., p. 75
oligonucleotide synthesis - Nov., p. 325
Orphan Drug Act - Apr., p. 103
patent disputes - May, p. 140; June, p. 169; July, p. 204; Aug., p. 236; Sep., p. 270; Oct., p. 300; Nov., p. 333; Dec., p. 362, 364, 366
patent disputes, HIV - July, p. 202
patent infringement - Feb., p. 41; Apr., p. 103
patent licensing (use licensing)
patents, AIDS-related full text - Dec., p. 363
pediatric trials - Oct., p. 296
Peoples Republic of China - Dec., p. 362
polymerase chain reaction (PCR) - Apr., p. 102
price controls - Mar., p. 73
pricing, federal inventions - Dec., p. 364
primate studies - July, p. 194; Oct., p. 292
public education - July, p. 197
quality of life - Mar., p. 67
R&D halted - Oct., p. 296; Dec., p. 359
recruiting, HIV vaccine trials - Feb., p. 40
research integrity - Feb., p. 42
Samoa - Aug., p. 235
SCID-hu mouse studies - Nov., p. 325
screening - Mar., p. 74; Apr., p. 101, 103; July, p. 206; Sep., p. 269; Dec., p. 364
surrogate markers - Sep., p. 259
TH1 to TH2 switch - Feb., p. 36
Thailand - Feb., p. 35; June, p. 171; Nov., p. 324
transgenic mice - July, p. 204
treatment costs, HIV-infection - July, p. 202
U.K. approvals - July, p. 202
unapproved treatments - Feb., p. 44
universal vaccinations - Dec., p. 362
vaccine heat stability - Apr., p. 102
viral load, HIV - Oct., p. 297
viral resistance, hepatitis C - Aug., p. 232
viral resistance, HIV - Mar., p. 69
viral shedding, HSV - Oct., p. 290
Virology on CD-ROM - Oct., p. 299
virus names - Aug., p. 233
warning letters, FDA - June, p. 165
warning letters, Japan - June, p. 169